Literature DB >> 28099231

Vemurafenib (BRAF Inhibitor) Therapy for Orbital Erdheim-Chester Disease.

Adit Gupta1, Amir Yeganeh, Daniel Rootman, Robert Goldberg.   

Abstract

Erdheim-Chester disease is a rare xanthogranulomatous systemic disease, which involves the orbit in some cases. Through this case report, the authors review the treatment modalities used in orbital Erdheim-Chester disease and explore a newer modality of treatment. Cases of orbital Erdheim-Chester disease were identified in the literature utilizing a PubMed search and all the treatment modalities were reviewed. The response to treatment of orbital Erdheim-Chester disease has been poor with the various medical and surgical treatment modalities used in the past. The authors report the use of BRAF inhibitor with a remarkable response in our case.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28099231     DOI: 10.1097/IOP.0000000000000866

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  4 in total

1.  Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAFV600E mutation.

Authors:  Moozhan Nikpanah; Lauren Kim; S Mojdeh Mirmomen; Rolf Symons; Ioannis Papageorgiou; William A Gahl; Kevin O'Brien; Juvianee I Estrada-Veras; Ashkan A Malayeri
Journal:  Eur Radiol       Date:  2018-03-19       Impact factor: 5.315

2.  Orbital and chorioretinal manifestations of Erdheim-Chester disease treated with vemurafenib.

Authors:  Laura C Huang; Katie L Topping; Dita Gratzinger; Ryanne A Brown; Beth A Martin; Ruwan A Silva; Andrea L Kossler
Journal:  Am J Ophthalmol Case Rep       Date:  2018-07-25

3.  Choroidal mass as the first presentation of Erdheim-Chester disease.

Authors:  Francesco Pichi
Journal:  Am J Ophthalmol Case Rep       Date:  2019-08-09

Review 4.  Repurposing host-based therapeutics to control coronavirus and influenza virus.

Authors:  Cui-Cui Li; Xiao-Jia Wang; Hwa-Chain Robert Wang
Journal:  Drug Discov Today       Date:  2019-01-31       Impact factor: 7.851

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.